During Friday’s Current trade, Shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA), gain 0.47% to $2.15.
Synta Pharmaceuticals Corp. (SNTA) declared the appointment of Alan C. Rigby, Ph.D., as the Company’s Senior Vice President and Chief Scientific Officer. Dr. Rigby brings over 20 years of academic and industry experience in the areas of structural and computational biology, drug discovery, and translational research of small and large molecules in oncology. Most recently, Dr. Rigby served as Vice President, Global Antibody Drug Conjugate Biology, Oncology Research, for Eli Lilly and Company at their New York site.
Preceding to joining Eli Lilly in 2010, Alan was the Principal Investigator of a National Institutes of Health (NIH) funded independent academic laboratory and the Director of the Drug Discovery and Target Validation Program within the Center for Vascular Biology at the Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Rigby has served and continues to serve on national and international granting councils counting the National Institutes of Health, National Science Foundation, Canadian Foundation for Innovation and Genome Quebec’s PRIVAC. He is the North American Editor for Current Computer Aided Drug Discovery and on the Editorial Advisory Board for Future Medicinal Chemistry. He has published more than 50 scientific papers, a book chapter and has more than 10 patents that have published or are pending. Dr. Rigby holds an Honors BSc. in Biochemistry and a Ph.D. in Biochemistry from the University of Western Ontario in Canada.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
Shares of Starwood Hotels & Resorts Worldwide Inc (NYSE:HOT), declined -2.05% to $72.16, during its current trading session.
Starwood Hotels & Resorts Worldwide, Inc. (HOT) declared that it has agreed to sell The Westin Excelsior Rome to Katara Hospitality for €222 million ($251 million in USD).
As part of the deal, the historic hotel will be renovated in the next five years, counting a top-to-bottom transformation of all guestrooms, in addition to upgrades to the hotel’s public areas. Additionally, as has been the case with other sales of Starwood hotel assets, it will continue to be operated by Starwood under a new long-term administration agreement.
Starwood Hotels & Resorts Worldwide, Inc., together with its auxiliaries, operates as a hotel and leisure company worldwide. The company owns, operates, and franchises luxury and upscale full-service hotels, resorts, residences, retreats, select-service hotels, and extended stay hotels under the St. Regis, The Luxury Collection, W, Westin, Le Méridien, Sheraton, Four Points, Aloft, and Element brand names.
Virgin America Inc (NASDAQ:VA), during its Friday’s current trading session decreased -0.95% to $37.40.
Virgin America Inc. (VA) stated its preliminary operational results for August 2015. The airline’s traffic (measured in revenue passenger miles) raised 1.5 percent on capacity (measured in accessible seat miles) that was 4.0% higher from the same month in 2014.
Virgin America Inc. provides planned air travel services. As of December 31, 2014, it offered services to 21 airports in the United States and Mexico with a fleet of about 53 Airbus single-aisle aircraft, counting of 10 Airbus A319s and 43 Airbus A320s. The company was formerly known as Best Air Holdings, Inc., and changed its name to Virgin America Inc. in November 2005. Virgin America Inc. was incorporated in 2004 and is headquartered in Burlingame, California.
Finally, Manitowoc Company Inc (NYSE:MTW), decreased -2.38%, to $16.21.
Finacity Corporation declared that it has facilitated the successful addition of an Asian Originator to an existing trade receivables securitization for The Manitowoc Company, Inc. (MTW). The $185 million transaction now incorporates a new division (Manitowoc Foodservice Asia Pacific Private Limited). Wells Fargo Capital Finance, a division of Wells Fargo & Company ( WFC) offered funding for the transaction, while Finacity offered structuring support and is responsible for ongoing program administration and reporting.
The Manitowoc Company, Inc. designs, manufactures, and sells cranes and related products, and foodservice equipment worldwide. The Cranes and Related Products segment offers lattice-boom cranes, counting crawler and truck mounted lattice-boom cranes, and crawler crane attachments; tower cranes comprising top slewing, luffing jib, topless, and self-erecting tower cranes; mobile telescopic cranes, such as rough terrain, all-terrain, truck mounted, and industrial cranes; and boom trucks comprising telescopic boom trucks under the Manitowoc, Potain, Grove, National Crane, and Shuttlelift brands.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
